Weizhen Medicine

Jiangsu Weizhen Biotechnology Co., Ltd. is a high-tech enterprise dedicated to developing cutting-edge proprietary molecular detection technologies. The company houses the "Early Cancer Prevention Testing Center of the Chinese Ministry of Health Medical Promotion Association," "Jiangsu Provincial Engineering Technology Research Center for Tumor Molecular Diagnosis," "Jiangsu Provincial Multidisciplinary Collaborative Diagnosis and Treatment Technology Service Center for Malignant Tumors," and "Jiangsu Provincial Key Laboratory of Molecular Biology and Translational Medicine for Malignant Tumors."
Founded in September 2008, after eight years of unremitting efforts, the company has grown into a high-tech, innovative pharmaceutical technology enterprise with an elite team of over 300 members, including overseas PhDs and master's degree holders from top universities, operating under a group-based management structure. It has built a 1,200㎡ modern office, a 1,000㎡ medical molecular laboratory, and a 2,000㎡ GMP production workshop certified under national (YY/T 0287-2003) and EU (TUV ISO 13485) quality management systems, and is currently constructing a 6,000㎡ independent integrated medical testing service center. The company has developed leading national technology platforms including PremiDTM:emoji:, qPCR-HRM, TaqMan-ARMS, eFusion-qPCR, qRM-qPCR, calibrated RNA technology, PNA-digital-PCR, and Emulsion-Flexsort, and has filed 37 patents, securing 78 domestic invention patents and 5 international invention patents. As of August 2013, it has obtained 2 molecular diagnostic kit licenses approved by the National Medical Products Administration, 2 medical device registration licenses, and 4 reagent registration licenses. Five pioneering molecular diagnostic products are in clinical trials, and some products have begun to go global.
Among these, the groundbreaking PremiD:emoji: molecular carcinogenesis ultra-early detection technology has been continuously reported by hundreds of media outlets, including China Government Network's China News, Xinhua Daily Telegraph, Science and Technology Daily, Wenhui Daily, Jiefang Daily, Sina.com, and Sohu.com, and has been featured in exclusive interviews on multiple digital media platforms such as CCTV-10, Jiangsu Satellite TV, and Suzhou TV. The company currently undertakes or participates in numerous major research projects at the national, provincial, and ministerial levels, including the National High-Tech R&D Program (863 Program), the China-Israel International Science and Technology Cooperation Project, provincial science and technology achievement transformation projects, and provincial science and technology infrastructure construction programs, securing 28 million yuan in research funding.
The company has established long-term cooperative relationships with prestigious domestic and international institutions and medical organizations, including Harvard Medical School, Tel Aviv University in Israel, the University of Hamburg in Germany, Nanjing Medical University, Peking Union Medical College Hospital, and Beijing 301 Hospital. Its products have been promoted and applied in nearly 100 top-tier (Class 3A) hospitals and physical examination centers nationwide.
Driven by innovation as the primary force, and built upon advanced molecular diagnostic technology platforms, our relentless pursuit is to construct an integrated cancer prevention and treatment system encompassing "ultra-early warning, auxiliary diagnosis, companion testing for medication, real-time postoperative monitoring, and individualized immune intervention."